CytomX Therapeutics Inc
NASDAQ:CTMX
CytomX Therapeutics Inc
NASDAQ:CTMX
Price:
4.67
USD
-2.1%
Market Cap:
$791.3m
Relative Value
The Relative Value of one
CTMX
stock under the Base Case scenario is
0.64
USD.
Compared to the current market price of 4.67 USD,
CytomX Therapeutics Inc
is
Overvalued by 86%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CTMX
Relative Value
Base Case
0.64
USD
Overvaluation 86%
Multiples Across Competitors
CTMX Competitors Multiples
CytomX Therapeutics Inc Competitors
CytomX Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
CytomX Therapeutics Inc
NASDAQ:CTMX
|
787.4m USD | 6.8 | 27.5 | 25.6 | 27 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
404.5B USD | 6.6 | 96.6 | 15.8 | 22 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.1B USD | 5.4 | 25.6 | 14.7 | 14.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
177.9B USD | 6.1 | 21.1 | 13.1 | 16.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.5B USD | 9.6 | 29.2 | 22 | 23 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 5.6 | 17.8 | 13.2 | 15.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70.3B AUD | 3.2 | 35.7 | 11.7 | 14.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.8B EUR | 10.8 | 34.7 | 37.6 | 38.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
